Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Enalapril
Drug ID BADD_D02425
Description Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling.[A18459] Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes vasoconstriction and renal reabsorption of sodium ions in the kidneys. Ultimately, enalaprilat works to reduce blood pressure and blood fluid volume. Commonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension. The active metabolite enalaprilat is also available in oral tablets and intravenous formulations for injection.
Indications and Usage For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.
Marketing Status Not Available
ATC Code C09AA02
DrugBank ID DB00584
KEGG ID D07892
MeSH ID D004656
PubChem ID 5388962
TTD Drug ID D00SEB
NDC Product Code 69238-2141
Synonyms Enalapril | MK-421 | MK 421 | MK421 | Renitec | Renitek | Enalapril Maleate | Maleate, Enalapril
Chemical Information
Molecular Formula C20H28N2O5
CAS Registry Number 75847-73-3
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Blood pressure decreasedAngiotensin-converting enzymeP12821T82577Not Available
CoughB2 bradykinin receptorP30411T23714Not Available
HepatotoxicityCytochrome P450 3A4P08684T37848Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperhidrosis23.02.03.004; 08.01.03.0280.000306%
Hyperkalaemia14.05.03.0010.000160%
Hypersensitivity10.01.03.0030.000459%
Hypertension24.08.02.0010.000612%
Hypertensive crisis24.08.01.0010.000459%Not Available
Hypotension24.06.03.0020.000918%
Insomnia19.02.01.002; 17.15.03.0020.000306%
Intestinal obstruction07.13.01.0020.000306%Not Available
Leukocytosis01.02.01.0020.000306%
Local swelling08.01.03.0130.000459%Not Available
Malaise08.01.01.0030.001071%
Nasopharyngitis22.07.03.002; 11.01.13.0020.000459%Not Available
Nausea07.01.07.001--
Neutrophilia01.02.01.0050.000306%Not Available
Oedema mouth23.04.01.008; 10.01.05.006; 07.05.04.0010.000306%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.000306%
Pain08.01.08.0040.000459%
Pain in extremity15.03.04.0100.000459%
Pancreatitis acute07.18.01.0020.000612%Not Available
Premature baby18.04.02.0010.000459%Not Available
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.0070.000765%
Pruritus23.03.12.0010.000306%
Pyrexia08.05.02.0030.000612%
Respiratory failure22.02.06.002; 14.01.04.0030.000080%
Stress19.06.02.0040.000459%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.000612%Not Available
Syncope24.06.02.012; 02.01.02.008; 17.02.04.0080.000459%
Tachycardia02.03.02.0070.000459%Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.000306%Not Available
Upper gastrointestinal haemorrhage07.12.02.006; 24.07.02.0240.000306%
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages